Researchers Investigate a Less Toxic Radiation Treatment for HPV-Positive Oropharynx Cancer
CHICAGO, IL (May 29, 2013)—Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.
Patients enrolled in the trial received an initial regimen of chemotherapy followed by treatment with the targeted therapy cetuximab, a monoclonal antibody. In the study, a patient's response to those initial treatments determined the dose during radiation treatment.
“Those patients who had a really good response to chemotherapy might also be more responsive to radiation,” says Barbara Burtness, senior author on the study and chief of head and neck medical oncology at Fox Chase. “Therefore, the use of a full dose of radiation for those patients might represent overtreatment.”
Burtness is also chair of the Eastern Cooperative Oncology Group (ECOG), which sponsors this ongoing trial. ECOG is a a National Cancer Institute-funded team of researchers who organize and carry out clinical trials.
According to the National Cancer Institute, more than 40,000 people will be diagnosed with cancer of the oropharynx—a swath of tissue at the back of the throat—in 2013, and nearly 8,000 will die from the disease. Between 60 and 80 percent of cases are associated with infection by Human Papilloma Viruses, or HPVs.
“Patients with HPV-associated oropharyngeal cancer tend to be younger than other oropharyngeal cancer patients, and would be living with the aftereffects of treatment for more years,” says Burtness. A patient who undergoes standard radiation to the back of the throat—usually between 66 and 70 Gy—may suffer serious side effects like dry mouth and disfunction in swallowing.
The investigators suspected a subset of HPV-associated oropharyngeal cancer patients, identified by their response to chemotherapy, may be suitable for trials of lower radiation.
Burtness and her co-investigators enrolled 90 patients in the trial, 80 of whom were analyzable. Of those patients, 95 percent were men, and the median age was 57. The researchers reported that most patients tolerated the induction chemotherapy and treatment with cetuximab, and 96 percent completed all three cycles. Forty-six patients had a complete clinical response, which meant all signs of the primary tumor had disappeared following treatment. These patients went on to receive a lower-than-standard dose of radiation, at 54 Gy.
The researchers report that most patients tolerated the treatment with low incidence of high-grade side effects, but other data are premature. The primary endpoint of the study is two-year progression-free survival, the fraction of patients whose diseases have not worsened after two years. The investigators say that if the two-year progression-free survival rate is at least 85 percent, further studies on lower-dose radiation are warranted.
“We do not expect that anyone would want to lower the dose of radiation based on this study, which is very much a developmental study,” says Burtness. “We've never had a comparative trial of low dose versus standard dose IMRT.”
Burtness notes among patients who received a lower dose of radiation, “what seemed to predict for a slightly worse outcome was either a heavy smoking history (more than 10 pack years), or those with larger tumors.”
She says that although it's too early to draw definitive conclusions, the early results “may justify further study of deintensifying radiation among nonsmokers with HPV-associated oropharyngeal cancers.”
In addition to Burtness and Marur, other investigators include Christine H. Chung at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD; David R. Trevarthen at the Swedish Medical Center in Denver; Shuli Li at the Dana-Farber Cancer Institute in Boston, MA; Weiqiang J. Zhao and Maura Gillison at the Ohio State University College of Medicine in Columbus, OH; Alexander D. Colevas at the Stanford Cancer Center in Stanford, Calif.; Anthony J. Cmelak at the Vanderbilt-Ingram Cancer Center in Nashville, TN; Julie E. Bauman at the University of Pittsburgh Medical Center, PA; Lynne I. Wagner at Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, IL; Balkrishna N. Jahagirdar at HealthPartners and Regions Cancer Care Center in St. Paul, MN; William H. Westra at the Johns Hopkins Hospital in Baltimore, MD; Robert Ferris at the University of Pittsburgh Cancer Institute, PA. The study is sponsored by ECOG.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).